You are here:
THE EFFECT OF IMIDAN ADMINISTERED TO PREGNANT RATS
Citation:
Short, R., J. Minor, T. Unger, B. Breeden, AND D. Goethem. THE EFFECT OF IMIDAN ADMINISTERED TO PREGNANT RATS. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/1-80/008 (NTIS PB80159627), 1980.
Description:
The purpose of this study was to evaluate the teratogenic potential of Imidan in Wistar rats. Accordingly, groups of pregnant Wistar rats received Imidan by either a single or multiple dose protocol and their fetuses were examined for gross, soft tissue, and skeletal defects. In the single dose protocol, 30 mg/kg of Imidan was administered on gestational day 8 or 12. In the multiple dose protocol 0.06, 1.5, or 30 mg/kg of Imidan was administered every other day during gestation for a total of nine doses. No mortality which was attributed to Imidan was observed. Morbidity, as measured by reduced food consumption and weight gain was observed in dams that received 40 mg/kg of Imidan by the single and multiple dose protocol. None of the observed anomalies were increased to a statistically significant degree. Therefore, it was concluded that Imidan was not a teratogen in this study.